Fig. 8.

Targeting NAT10 in ESCC cells enhances the efficacy of PD-1 therapy by modulating macrophage reprogramming Animal models were established by subcutaneously inoculating AKR cells stably transfected with sh-NC or sh-NAT10#1 on the right dorsal side of four groups of mice. Two of these groups underwent PD-1 therapy. A, B. Tumor size and weight were observed and measured in the four groups of mice. C–E. Tumor tissues isolated from the four groups were subjected to IHC staining to measure the expression of NAT10, CD163, and CD86. *P < 0.05, ^⁎⁎P < 0.01.